BTK and non-Hodgkin lymphoma: In univariate analysis conducted using a logistic regression model, B-NHL (HR=3.7, 95% CI 1.4–10.0, P=0.009; Figure 3), anti-CD20 therapy (HR=2.3, 95% CI 1.0–5.2, P=0.050), BTK inhibitor (HR=3.6, 1.8–7.4, P<0.001), active therapy (HR=3.0, 1.5–5.7, P=0.001), and lack of disease remission (HR=3.7, 1.8–7.4, P=0.001) were high-risk factors for developing pneumonia in our study population.